News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
751,816 Results
Type
Article (44469)
Company Profile (397)
Press Release (706937)
Multimedia
Podcasts (152)
Webinars (24)
Section
Business (209640)
Career Advice (2052)
Deals (36280)
Drug Delivery (145)
Drug Development (84264)
Employer Resources (174)
FDA (16855)
Job Trends (15248)
News (354952)
Policy (33321)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (4)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2701)
Accelerated approval (59)
ADA (49)
Adcomms (33)
Allergies (199)
Alliances (51123)
ALS (236)
Alzheimer's disease (1918)
Antibody-drug conjugate (ADC) (558)
Approvals (17306)
Artificial intelligence (769)
ASCO (337)
Autoimmune disease (364)
Automation (63)
Bankruptcy (376)
Best Places to Work (11840)
BIO (74)
BIOSECURE Act (20)
Biosimilars (240)
Biotechnology (280)
Bladder cancer (209)
Brain cancer (79)
Breast cancer (826)
Cancer (6524)
Cardiovascular disease (530)
Career advice (1749)
Career pathing (47)
CAR-T (371)
CDC (60)
Celiac Disease (3)
Cell therapy (1018)
Cervical cancer (56)
Clinical research (73567)
Collaboration (2344)
Commercialization (1)
Company closure (5)
Compensation (1557)
Complete response letters (97)
COVID-19 (2820)
CRISPR (125)
C-suite (1313)
Cystic fibrosis (167)
Data (8845)
Decentralized trials (3)
Denatured (47)
Depression (190)
Dermatology (102)
Diabetes (683)
Diagnostics (7108)
Digital health (66)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (390)
Drug pricing (215)
Drug shortages (32)
Duchenne muscular dystrophy (330)
Earnings (93555)
Editorial (73)
Employer branding (21)
Employer resources (156)
Events (124519)
Executive appointments (1174)
FDA (20974)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (36)
Funding (1950)
Gene editing (268)
Generative AI (65)
Gene therapy (818)
GLP-1 (1151)
Government (4856)
Grass and pollen (6)
Guidances (422)
Healthcare (19500)
Hematology (194)
HIV (93)
Huntington's disease (66)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (117)
Immunology and inflammation (337)
Immuno-oncology (116)
Indications (225)
Infectious disease (3196)
Inflammatory bowel disease (235)
Inflation Reduction Act (17)
Influenza (147)
Intellectual property (326)
Interviews (321)
IPO (16975)
IRA (53)
Job creations (3721)
Job search strategy (1444)
JPM (67)
Kidney cancer (21)
Labor market (112)
Layoffs (613)
Leadership (44)
Legal (8033)
Liver cancer (105)
Longevity (36)
Lung cancer (861)
Lymphoma (486)
Machine learning (66)
Management (61)
Manufacturing (1192)
Marketing (5)
MASH (219)
Medical affairs (1)
Medical device (14160)
Medtech (14336)
Mergers & acquisitions (20634)
Metabolic disorders (1733)
mRNA (261)
Multiple sclerosis (206)
NASH (20)
Neurodegenerative disease (498)
Neuropsychiatric disorders (120)
Neuroscience (3647)
Neurotech (1)
NextGen: Class of 2026 (6779)
Non-profit (4613)
Now hiring (83)
Obesity (809)
Opinion (325)
Ovarian cancer (246)
Pain (275)
Pancreatic cancer (365)
Parkinson's disease (417)
Partnered (37)
Patents (652)
Patient recruitment (803)
Peanut (68)
People (61447)
Pharmaceutical (67)
Pharmacy benefit managers (34)
Phase 1 (23137)
Phase 2 (32463)
Phase 3 (23974)
Pipeline (10119)
Policy (348)
Postmarket research (2608)
Preclinical (9902)
Press Release (67)
Prostate cancer (346)
Psychedelics (69)
Radiopharmaceuticals (370)
Rare diseases (1271)
Real estate (6085)
Recruiting (72)
Regulatory (26459)
Reports (56)
Research institute (2526)
Resumes & cover letters (356)
Rett syndrome (46)
RNA editing (30)
RSV (90)
Schizophrenia (192)
Series A (337)
Series B (249)
Service/supplier (9)
Sickle cell disease (132)
Special edition (30)
Spinal muscular atrophy (175)
Sponsored (49)
Startups (3845)
State (2)
Stomach cancer (19)
Supply chain (138)
Tariffs (88)
The Weekly (102)
Vaccines (1190)
Venture capital (132)
Weight loss (523)
Women's health (143)
Worklife (22)
Date
Today (145)
Last 7 days (466)
Last 30 days (2281)
Last 365 days (31380)
2026 (17057)
2025 (31055)
2024 (36219)
2023 (41016)
2022 (52277)
2021 (56760)
2020 (54922)
2019 (47418)
2018 (35701)
2017 (33031)
2016 (32352)
2015 (38398)
2014 (32190)
2013 (27115)
2012 (29221)
2011 (29868)
2010 (27998)
Location
Africa (760)
Alabama (100)
Alaska (7)
Arizona (377)
Arkansas (16)
Asia (41484)
Australia (6911)
California (14341)
Canada (4026)
China (1572)
Colorado (616)
Connecticut (633)
Delaware (439)
Europe (91339)
Florida (2147)
Georgia (457)
Hawaii (3)
Idaho (63)
Illinois (1184)
India (101)
Indiana (638)
Iowa (26)
Japan (610)
Kansas (137)
Kentucky (54)
Louisiana (59)
Maine (76)
Maryland (1698)
Massachusetts (10404)
Michigan (380)
Minnesota (776)
Mississippi (6)
Missouri (151)
Montana (35)
Nebraska (30)
Nevada (151)
New Hampshire (89)
New Jersey (3760)
New Mexico (33)
New York (3749)
North Carolina (1860)
North Dakota (10)
Northern California (7235)
Ohio (428)
Oklahoma (23)
Oregon (43)
Pennsylvania (2830)
Puerto Rico (31)
Rhode Island (53)
South America (1127)
South Carolina (88)
South Dakota (2)
Southern California (5672)
Tennessee (234)
Texas (2296)
United States (50712)
Utah (425)
Vermont (2)
Virginia (352)
Washington D.C. (82)
Washington State (1162)
West Virginia (4)
Wisconsin (139)
Wyoming (2)
751,816 Results for "dmd therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
The FDA plans to hold an advisory committee meeting to discuss Capricor Therapeutics’ application for deramiocel, which the agency rejected last July. The news surprised CEO Linda Marbán, who told
BioSpace
the FDA has not communicated any issues of concern with the company’s resubmitted application.
June 26, 2026
·
4 min read
·
Heather McKenzie
Press Releases
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
·
7 min read
Press Releases
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
May 20, 2026
·
10 min read
Press Releases
GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual Meeting
May 14, 2026
·
8 min read
Press Releases
Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD
June 18, 2026
·
6 min read
Press Releases
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
March 9, 2026
·
9 min read
Press Releases
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
May 14, 2026
·
12 min read
Duchenne muscular dystrophy
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
February 9, 2026
·
11 min read
·
Heather McKenzie
Press Releases
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026
·
9 min read
Press Releases
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
April 27, 2026
·
6 min read
1 of 75,182
Next
